Molecular Oncology
Volume 3, Issue 2 , Pages 138-150 , April 2009

The Contribution of BRCA1 and BRCA2 to Ovarian Cancer

Received 1 January 2009 ,Revised 1 February 2009 ,Accepted 2 February 2009.

References 

  1. Anton-Culver H, Cohen PF, Gildea ME, Ziogas A. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur. J. Cancer. 2000;36:1200–1208
  2. Antoniou AC, Pharoah PD, McMullan G, Day NE, Stratton MR, Peto J, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br. J. Cancer. 2002;86:76–83
  3. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 2003;72:1117–1130
  4. Antoniou AC, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J. Med. Genet. 2005;42:602–603
  5. Antoniou AC, Hardy R, Walker L, Evans DG, Shenton A, Eeles R, et al Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J. Med. Genet. 2008;45:425–431
  6. Ben David Y, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, Beller U, et al Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J. Clin. Oncol. 2002;20:463–466
  7. Berchuck A, Heron KA, Carney ME, Lancaster JM, Fraser EG, Vinson VL, et al Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin. Cancer Res. 1998;4:2433–2437
  8. Bergman A, Flodin A, Engwall Y, Arkblad EL, Berg K, Einbeigi Z, et al. A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques. Fam. Cancer. 2005;4:89–96
  9. Bergthorsson JT, Ejlertsen B, Olsen JH, Borg A, Nielsen KV, Barkardottir RB, et al BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age. J. Med. Genet. 2001;38:361–368
  10. Bermejo-Pérez MJ, Márquez-Calderón S, Llanos-Méndez A. Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int. J. Cancer. 2007;121:225–231
  11. Bjørge T, Lie AK, Hovig E, Gislefoss RE, Hansen S, Jellum E, et al. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. Br. J. Cancer. 2004;91:1829–1834
  12. Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, et al Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000;283:2260–2265
  13. Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF, Koonin EV. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J. 1997;11:68–76
  14. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 2007;25:1329–1333
  15. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE, et al. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res. 2007;9:104
  16. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J. Clin. Oncol. 2008;26:20–25
  17. Collins N, McManus R, Wooster R, Mangion J, Seal S, Lakhani SR, et al Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene. 1995;10:1673–1675
  18. Culver J, Lowstuter K, Bowling L. Assessing breast cancer risk and BRCA1/2 carrier probability. Breast Dis. 2006;27:5–20
  19. Díez O, Osorio A, Durán M, Martinez-Ferrandis JI, de la, Hoya M, et al Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum. Mutat. 2003;22:301–312
  20. Dørum A, Hovig E, Tropé C, Inganas M, Møller P. Three percent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA. Eur. J. Cancer. 1999;35:779–781
  21. Drew Y, Calvert H. The potential of PARP inhibitors in genetic breast and ovarian cancers. Ann. N.Y. Acad. Sci. 2008;1138:136–145
  22. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447:1087–1093
  23. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, et al Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet. 2008;40:316–321
  24. Einbeigi Z, Bergman A, Meis-Kindblom JM, Flodin A, Bjursell C, Martinsson T, et al Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden. Fam. Cancer. 2007;6:35–41
  25. Elmasry K, Gayther SA. Epidemiology of ovarian cancer. In:  Reznek R editors. Cancer of the Ovary. UK: Cambridge University Press; 2007;p. 115–126
  26. Evans DG, Howell A. Breast cancer risk-assessment models. Breast Cancer Res. 2007;9:213
  27. Evans DG, Young K, Bulman M, Shenton A, Wallace A, Lalloo F. Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families. Clin. Genet. 2008;73:338–345
  28. Ferla R, Calò V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, et al. Founder mutations in BRCA1 and BRCA2 genes. Ann. Oncol. 2007;18(Suppl. 6):vi93–vi98
  29. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 1998;62:676–689
  30. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, et al Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J. Clin. Oncol. 2002;20:1480–1490
  31. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed. 2005;7:60
  32. Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, et al Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat. Genet. 1995;11:428–433
  33. Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat. Genet. 1997;15:103–105
  34. Gayther SA, Russell P, Harrington P, Antoniou AC, Easton DF, Ponder BA. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am. J. Hum. Genet. 1999;65:1021–1029
  35. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006;25:5864–5874
  36. Gudmundsson J, Sulem P, Rafnar T, Bergthorsson JT, Manolescu A, Gudbjartsson D, et al Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat. Genet. 2008;40:281–283
  37. Górski B, Menkiszak J, Gronwald J, Lubinski J, Narod SA. A protein truncating BRCA1 allele with a low penetrance of breast cancer. J. Med. Genet. 2004;41:e130
  38. Górski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, et al A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int. J. Cancer. 2004;110:683–686
  39. Gerdes AM, Cruger DG, Thomassen M, Kruse TA. Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families. Clin. Genet. 2006;69:171–178
  40. Ginolhac SM, Gad S, Corbex M, Bressac-De-Paillerets B, Chompret A, Bignon YJ, et al BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations. Cancer Epidemiol. Biomarkers Prev. 2003;12:90–95
  41. Hirsh-Yechezkel G, Chetrit A, Lubin F, Friedman E, Peretz T, Gershoni R, et al. Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel. Gynecol. Oncol. 2003;89:494–498
  42. Hughes DJ, Ginolhac SM, Coupier I, Corbex M, Bressac-de-Paillerets B, Chompret A, et al Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers. Cancer Epidemiol. Biomarkers Prev. 2005;14:265–267
  43. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, et al A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 2007;39:870–874
  44. Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, et al High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res. 1996;56:3663–3665
  45. Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S, et al Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin. Cancer Res. 2004;10:2473–2481
  46. Liede A, Malik IA, Aziz Z, Rios Pd Pde L, Kwan E, Narod SA. Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. Am. J. Hum. Genet. 2002;71:595–606
  47. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr. Opin. Pharmacol. 2008;8:363–369
  48. Lubinski J, Phelan CM, Ghadirian P, Lynch HT, Garber J, Weber B, et al Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam. Cancer. 2004;3:1–10
  49. McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, et al Hereditary Ovarian Cancer Clinical Study Group. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol. 2007;8:26–34
  50. Malander S, Ridderheim M, Måsbäck A, Loman N, Kristoffersson U, Olsson H, et al. One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden. Eur. J. Cancer. 2004;40:422–428
  51. Mann GJ, Thorne H, Balleine RL, Butow PN, Clarke CL, Edkins E, et al Kathleen Cuningham Consortium for Research in Familial Breast Cancer Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res. 2006;8:R12
  52. Matsushima M, Kobayashi K, Emi M, Saito H, Saito J, Suzumori K, et al. Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation. Hum. Mol. Genet. 1995;4:1953–1956
  53. Mazoyer S. Genomic rearrangements in the BRCA1 and BRCA2 genes. Hum. Mutat. 2005;25:415–422
  54. Meindl A, German Consortium for Hereditary Breast and Ovarian Cancer . Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int. J. Cancer. 2002;97:472–480
  55. Menkiszak J, Gronwald J, Górski B, Jakubowska A, Huzarski T, Byrski T, et al Hereditary ovarian cancer in Poland. Int. J. Cancer. 2003;106:942–945
  56. Meyer P, Voigtlaender T, Bartram CR, Klaes R. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany. Hum. Mutat. 2003;22:259
  57. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71
  58. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, et al Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 2001;345:235–240
  59. Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, et al BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am. J. Hum. Genet. 2000;66:1259–1272
  60. Neuhausen SL, Godwin AK, Gershoni-Baruch R, Schubert E, Garber J, Stoppa-Lyonnet D, et al Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am. J. Hum. Genet. 1998;62:1381–1388
  61. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104:2807–2816
  62. Pal T, Permuth-Wey J, Kapoor R, Cantor A, Sutphen R. Improved survival in BRCA2 carriers with ovarian cancer. Fam. Cancer. 2007;6:113–119
  63. Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, Mazoyer S. The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum. Mol. Genet. 2002;11:2805–2814
  64. Petrij-Bosch A, Peelen T, vanVliet M, vanEijk R, Olmer R, Drusedau M, et al BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat. Genet. 1997;17:341–345
  65. Pharoah PDP, Easton DF, Stockton DL, Gayther SA, Ponder BAJ. Survival in familial, BRCA1 and BRCA2 associated epithelial ovarian cancer. Cancer Res. 1999;59:868–871
  66. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat. Genet. 2002;31:33–36
  67. Phelan CM, Kwan E, Jack E, Li S, Morgan C, Aubé J, et al. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast–ovarian cancer families. Hum. Mutat. 2002;20:352–357
  68. Pohlreich P, Zikan M, Stribrna J, Kleibl Z, Janatova M, Kotlas J, et al High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Res. 2005;7:R728–R736
  69. Puget N, Sinilnikova OM, Stoppa-Lyonnet D, Audoynaud C, Pages S, Lynch HT, et al. An Alu-mediated 6-kb duplication in the BRCA1 gene: a new founder mutation?. Am. J. Hum. Genet. 1999;64:300–302
  70. Rafnar T, Benediktsdottir KR, Eldon BJ, Gestsson T, Saemundsson H, Olafsson K, et al. BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study. Eur. J. Cancer. 2004;40:2788–2793
  71. Ramus SJ, Fishman A, Pharoah PD, Yarkoni S, Altaras M, Ponder BA. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations. Eur. J. Surg. Oncol. 2001;27:278–281
  72. Ramus SJ, Harrington P, Pye C, DiCioccio R, Cox M, Garlinghouse-Jones K, et al The contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. Hum. Mutat. 2007;28:1207–1215
  73. Richards WE, Gallion HH, Schmittschmitt JP, Holladay DV, Smith SA. BRCA1-related and sporadic ovarian cancer in the same family: implications for genetic testing. Gynecol. Oncol. 1999;75:468–472
  74. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, et al Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario. Canada. J. Natl. Cancer Inst. 2001;98:1694–1706
  75. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet. 2001;68:700–710
  76. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, et al Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N. Engl. J. Med. 1996;335:1413–1416
  77. Rubin SC, Blackwood MA, Bandera C, Behbakht K, Benjamin I, Rebbeck TR, et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am. J. Obstet. Gynecol. 1998;178:670–677
  78. Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin. Cancer Res. 2002;8:3776–3781
  79. Sarantaus L, Vahteristo P, Bloom E, Tamminen A, Unkila-Kallio L, Butzow R, et al. BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients. Eur. J. Hum. Genet. 2001;9:424–430
  80. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell. 1997;88:265–275
  81. Sinilnikova OM, Mazoyer S, Bonnardel C, Lynch HT, Narod SA, Lenoir GM. BRCA1 and BRCA2 mutations in breast and ovarian cancer syndrome: reflection on the Creighton University historical series of high risk families. Fam. Cancer. 2006;5:15–20
  82. Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat. Genet. 1992;2:128–131
  83. Smith SA, Richards WE, Caito K, Hanjani P, Markman M, DeGeest K, et al. BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study. Gynecol. Oncol. 2001;83:586–592
  84. Søgaard M, KrugerKjaer S, Cox M, Wozniak E, Hogdall E, Hogdall C, et al. BRCA1 and BRCA2 mutation prevalence and clinical characteristics in an ovarian cancer case population from Denmark clin. Cancer Res. 2008;14:3761–3767
  85. Sokolenko AP, Rozanov ME, Mitiushkina NV, Sherina NY, Iyevleva AG, Chekmariova EV, et al Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia. Fam. Cancer. 2007;6:281–286
  86. Stratton JF, Pharoah PDP, Smith SK, Easton DF, Ponder BAJ. A systematic review and meta- analysis of family history and risk of ovarian cancer. Br. J. Obstet. Gynaecol. 1998;105:493–499
  87. Stratton JF, Gayther SA, Russell P, Dearden J, Gore M, Blake P, et al. Contribution of BRCA1 mutations to ovarian cancer. N. Engl. J. Med. 1997;336:1125–1130
  88. Takahashi H, Behbakht K, McGovern PE, Chiu HC, Couch FJ, Weber BL, et al Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res. 1995;55:2998–3002
  89. Takahashi H, Chiu HC, Bandera CA, Behbakht K, Liu PC, Couch FJ, et al Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res. 1996;56:2738–2741
  90. Tenesa A, Farrington SM, Prendergast JG, Porteous ME, Walker M, Haq N, et al Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat. Genet. 2008;40:631–637
  91. The BRCA1 Exon 13 Duplication Screening Group . The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. Am. J. Hum. Genet. 2000;67:207–212
  92. The Breast Cancer Linkage Consortium . Cancer Risks in BRCA2 mutation carriers. J. Natl. Cancer Inst. 1999;91:1310–1316
  93. Thompson D, Easton D, the BCLC . Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am. J. Hum. Genet. 2001;68:410–419
  94. Thompson D, Easton D, Breast Cancer Linkage Consortium . Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol. Biomarkers Prev. 2002;11:329–336
  95. Thompson D, Easton DF, the BCLC . Cancer incidence in BRCA1 mutations carriers. J. Natl. Cancer Inst. 2002;94:1358–1365
  96. Tomlinson IP, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, Pittman AM, et al A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat. Genet. 2008;40:623–630
  97. Tonin PN, Mes-Masson AM, Narod SA, Ghadirian P, Provencher D. Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. Clin. Genet. 1999;55:318–324
  98. Van Der Looij M, Szabo C, Besznyak I, Liszka G, Csokay B, Pulay T, et al. Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. Int. J.Cancer. 2000;86:737–740
  99. Verhoog LC, van den, Ouweland AM, Berns E, vanVeghel-Plandsoen MM, vanStaveren IL, et al Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Eur. J. Cancer. 2001;37:2082–2090
  100. Ware MD, DeSilva D, Sinilnikova OM, Stoppa-Lyonnet D, Tavtigian SV, Mazoyer S. Does nonsense-mediated mRNA decay explain the ovarian cancer cluster region of the BRCA2 gene?. Oncogene. 2006;25:323–328
  101. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789–792
  102. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am. J. Epidemiol. 1992;136:1212–1220
  103. Whittemore AS, Balise RR, Pharoah PD, Dicioccio RA, Oakley-Girvan I, Ramus SJ, et al Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 Mutations. Br. J. Cancer. 2004;91:1911–1915
  104. Yazici H, Glendon G, Yazici H, Burnie SJ, Saip P, Buyru F, et al. BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases. Hum. Mutat. 2002;20:28–34
  105. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004;95:866–871

PII: S1574-7891(09)00027-1

doi: 10.1016/j.molonc.2009.02.001

Molecular Oncology
Volume 3, Issue 2 , Pages 138-150 , April 2009

Article Tools

* Image Usage & Resolution